AstraZeneca Plc submitted its antibody cocktail for U.S. emergency approval to prevent Covid-19 infection as therapeutic options for the pandemic broaden beyond vaccination.
It’s the first regulatory filing for the medicine, which was 77% effective in preventing symptomatic Covid in a clinical trial that included patients with high-risk factors for severe infection.
The cocktail can supplement vaccines for people who haven’t mounted a strong response to the shots -- or to protect those who couldn’t be immunized. The news comes just days after Merck & Co. fueled optimism that it will soon have the first Covid pill. Both treatments could offer a